Guardant Health Inc (GH : NASDAQ)
Common Stock
$13.65
USD
-159.60 (-92.12%)
Last updated: 2026-10-27
Follow GH
GH
Guardant Health Inc
WealthAwesomePerformance
1 Day
+2.78%
1 Week
+9.51%
1 Month
+0.46%
YTD
+75.01%
Key Statistics
Market Cap
$23.89B
52W High
$191.05
52W Low
$74.55
P/E Ratio
-
50 Day MA
$168.60
200 Day MA
$129.38
Beta
1.58
Dividend Yield
-
Advertisement
Technical Indicators
Price vs 50-Day SMA
Price vs 200-Day SMA
Recent Price History
| Date | Open | High | Low | Close | Adj Close | Volume |
|---|---|---|---|---|---|---|
| 10/27/2026 | $173.74 | $178.69 | $172.60 | $178.06 | $178.06 | 1,464,300 |
| 10/26/2026 | $170.10 | $175.08 | $168.73 | $173.25 | $173.25 | 1,981,232 |
| 10/23/2026 | $163.16 | $171.73 | $160.72 | $169.08 | $169.08 | 1,669,600 |
| 10/22/2026 | $165.03 | $167.25 | $158.68 | $162.94 | $162.94 | 1,770,462 |
| 10/21/2026 | $162.29 | $171.22 | $162.00 | $166.66 | $166.66 | 2,525,637 |
| 10/20/2026 | $158.29 | $163.56 | $155.07 | $162.59 | $162.59 | 1,308,429 |
| 10/19/2026 | $160.65 | $163.91 | $155.00 | $157.88 | $157.88 | 1,869,709 |
| 10/16/2026 | $165.88 | $168.47 | $157.44 | $158.60 | $158.60 | 1,975,600 |
| 10/15/2026 | $160.78 | $168.86 | $159.00 | $165.88 | $165.88 | 1,322,049 |
| 10/14/2026 | $159.89 | $166.16 | $159.00 | $162.99 | $162.99 | 1,277,790 |
Analyst Price Targets
Based on 26 analysts covering GH · as of Oct 28, 2026
Wall Street analysts forecast GH stock price to rise 1381.6% over the next 12 months.
Consensus
Strong Buy4.73 / 5.00
Avg. Target
US$202.24
+1381.6% Upside
Previously US$201.64 on Oct 26, 2026
Current Price
US$13.65
Last close
Analyst Breakdown (26 analysts)
Targets are snapshotted when they change. Unchanged figures keep their original date. Not financial advice.
Wealth Awesome Price Forecast
WA ModelStatistical 90-day price range based on GH's historical volatility
30-Day Vol
46.0%
Annualized
90-Day Vol
51.5%
Annualized
Trend (90d)
+48.0%
Annualized drift
90d Mean
US$211.36
Expected price
| Horizon | Expected | 68% Range (1σ) |
|---|---|---|
| 30 trading days | US$188.53 | US$160.87 – US$220.95 |
| 60 trading days | US$199.62 | US$159.49 – US$249.84 |
| 90 trading days | US$211.36 | US$160.57 – US$278.22 |
Methodology: Range is calculated using 30-day realized volatility via geometric Brownian motion (log-normal model). 68% band = ±1σ, 95% band = ±2σ. This is a statistical model, not a prediction. Past volatility does not guarantee future results. Not financial advice.
About Guardant Health Inc
Guardant Health, Inc., a precision oncology company, provides blood and tissue tests, and data sets in the United States and internationally. The company offers Guardant360 CDx test, a liquid biopsy test for tumor mutation profiling; Guardant360 Liquid test, which measures 740+ genes and supports all guideline-recommended biomarkers; Guardant Reveal test, a blood test that utilizes circulating tumor DNA to detect cancer at the molecular level; and Guardant360 Tissue test, a molecular profiling test for tumor tissue that provides genomic, transcriptomic, and epigenomic insights. It also provides Shield blood test for colorectal cancer screening in adults. In addition, the company offers GuardantINFINITY test that provides insights into the complexities of tumor molecular profiles and immune response to advance cancer research and therapy development; GuardantOMNI test covers 500 genes, including genes associated with homologous recombination repair deficiency and biomarkers for immuno-oncology applications; GuardantINFORM, which provides longitudinal biological insight into tumor evolution alongside longitudinal clinical outcomes; and GuardantConnect, an integrated software-based solution designed for clinical and biopharmaceutical customers to connect patients tested with assays with actionable alterations with potentially relevant clinical studies. Further, it provides Smart Platform, which delivers multiomic insights leveraging genomic, epigenomic, and RNA-based data that are scalable from research to the clinic. Additionally, the company offers development services, including companion diagnostic development and regulatory approval, clinical study setup, monitoring and maintenance, testing development and support, technologies licensing, and kit fulfillment and delivery of Shield screening tests. It has a strategic collaboration with Nuvalent, Inc. for oncology drug development. The company was incorporated in 2011 and is headquartered in Palo Alto, California.
Financials
- Revenue (TTM)
- $1.18B
- EBITDA
- $-430.57M
- Profit Margin
- -38.33%
- ROE (TTM)
- -4584.47%
- EPS (Diluted)
- -3.50
- Book Value
- -1.67
Classification
- Sector
- Health Care
- Industry
- Health Care Providers & Services
- Group
- Health Care Equipment & Services
7 stocks to buy and hold forever
Blue-chip dividend stocks for long-term wealth building.
Get the FREE ReportExplore More
Advertisement
Common Questions About GH.US
Market movers
Recent NASDAQ movers
Top 1-day gainers — updated from our Canadian movers feed.
| Ticker | Name | Price | 1D |
|---|---|---|---|
| NUWE | Nuwellis Inc | $5.41 | +1590.63% |
| ENLV | Enlivex Therapeutics Ltd | $2.70 | +1460.69% |
| QETAR | Quetta Acquisition Corporation Right | $0.68 | +70.00% |
| BRAI | Braiin Limited Common Stock | $3.31 | +56.13% |
| IRHOR | Iron Horse Acquisitions Corp. II Rights | $0.14 | +49.83% |
| FSHPR | Flag Ship Acquisition Corp. Right | $0.10 | +47.06% |
| AEYE | AudioEye Inc | $10.14 | +36.66% |
| MBRX | Moleculin Biotech Inc | $9.27 | +30.77% |
GH.US news timeline
8 articles covering GH.US, most recent first
LatestGuardant Health’s Undervaluation Claim Puts Patent Risks in Focus
October 2026
- Guardant Health Is Up 6.6% This Week. What's Behind the Move?
- Guardant Health Wins a New Breast Cancer Role: What Investors Should Know
- Guardant Health’s Shield and Reveal Data Valuation Debate: What Investors Should Know
- A Week of Losses for Guardant Health: What the Chart and the News Say
- Grail vs Guardant Health: Which is a Better Stock to Buy?
- Guardant Health Inc Stock Slides 8.8% on Heavy Volume: What's Behind the Move?
- Guardant Health's COSMOS Study Confirms Effectiveness of Liquid Biopsy for Melanoma Recurrence